@article{LueckerathLapaAlbertetal.2015,
  author    = {L{\"u}ckerath, Katharina and Lapa, Constantin and Albert, Christa and Herrmann, Ken and J{\"o}rg, Gerhard and Samnick, Samuel and Einsele, Herrmann and Knop, Stefan and Buck, Andreas K.},
  title     = {\(^{11}\)C-Methionine-PET: a novel and sensitive tool for monitoring of early response to treatment in multiple myeloma},
  series = {Oncotarget},
  volume    = {6},
  journal   = {Oncotarget},
  number    = {10},
  doi       = {10.18632/oncotarget.3053},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-148688},
  pages     = {8418-8429},
  year      = {2015},
  abstract  = {Multiple myeloma (MM) remains an essentially incurable hematologic malignancy. However, new treatment modalities and novel drugs have been introduced and thus additional tools for therapy monitoring are increasingly needed. Therefore, we evaluated the radiotracers \(^{11}\)C-Methionine (paraprotein-biosynthesis) and \(^{18}\)F-FDG (glucose-utilization) for monitoring response to anti-myeloma-therapy and outcome prediction. Influence of proteasome-inhibition on radiotracer-uptake of different MM cell-lines and patient-derived CD138\(^{+}\) plasma cells was analyzed and related to tumor-biology. Mice xenotransplanted with MM. 1S tumors underwent MET- and FDG-\(\mu\)PET. Tumor-to-background ratios before and after 24 h, 8 and 15 days treatment with bortezomib were correlated to survival. Treatment reduced both MET and FDG uptake; changes in tracer-retention correlated with a switch from high to low CD138-expression. In xenotransplanted mice, MET-uptake significantly decreased by 30-79\% as early as 24 h after bortezomib injection. No significant differences were detected thus early with FDG. This finding was confirmed in patient-derived MM cells. Importantly, early reduction of MET-but not FDG-uptake correlated with improved survival and reduced tumor burden in mice. Our results suggest that MET is superior to FDG in very early assessment of response to anti-myeloma-therapy. Early changes in MET-uptake have predictive potential regarding response and survival. MET-PET holds promise to individualize therapies in MM in future.},
  language  = {en}
}
@article{KolbMaeurerGoebelerMaeurer2015,
  author    = {Kolb-M{\"a}urer, Annette and Goebeler, Matthias and M{\"a}urer, Mathias},
  title     = {Cutaneous adverse events associated with interferon-\(\beta\) treatment of multiple sclerosis},
  series = {International Journal of Molecular Sciences},
  volume    = {16},
  journal   = {International Journal of Molecular Sciences},
  doi       = {10.3390/ijms160714951},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-148451},
  pages     = {14951-14960},
  year      = {2015},
  abstract  = {Interferons are widely used platform therapies as disease-modifying treatment of patients with multiple sclerosis. Although interferons are usually safe and well tolerated, they frequently cause dermatological side effects. Here, we present a multiple sclerosis (MS) patient treated with interferon-\(\beta\) who developed new-onset psoriasis. Both her MS as well as her psoriasis finally responded to treatment with fumarates. This case illustrates that interferons not only cause local but also systemic adverse events of the skin. These systemic side effects might indicate that the Th17/IL-17 axis plays a prominent role in the immunopathogenesis of this individual case and that the autoimmune process might be deteriorated by further administration of interferons. In conclusion, we think that neurologists should be aware of systemic cutaneous side effects and have a closer look on interferon-associated skin lesions. Detection of psoriasiform lesions might indicate that interferons are probably not beneficial in the individual situation. We suggest that skin lesions may serve as biomarkers to allocate MS patients to adequate disease-modifying drugs.},
  language  = {en}
}
@article{ReichertsGerdesPaulietal.2016,
  author    = {Reicherts, Philipp and Gerdes, Antje B. M. and Pauli, Paul and Wieser, Matthias J.},
  title     = {Psychological placebo and nocebo effects on pain rely on expectation and previous experience},
  series = {Journal of Pain},
  volume    = {17},
  journal   = {Journal of Pain},
  number    = {2},
  doi       = {10.1016/j.jpain.2015.10.010},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-190962},
  pages     = {203-214},
  year      = {2016},
  abstract  = {Expectation and previous experience are both well established key mediators of placebo and nocebo effects. However, the investigation of their respective contribution to placebo and nocebo responses is rather difficult because most placebo and nocebo manipulations are contaminated by pre-existing treatment expectancies resulting from a learning history of previous medical interventions. To circumvent any resemblance to classical treatments, a purely psychological placebonocebo manipulation was established, namely, the "visual stripe pattern induced modulation of pain." To this end, experience and expectation regarding the effects of different visual cues (stripe patterns) on pain were varied across 3 different groups, with either only placebo instruction (expectation), placebo conditioning (experience), or both (expectation + experience) applied. Only the combined manipulation (expectation + experience) revealed significant behavioral and physiological placebo nocebo effects on pain. Two subsequent experiments, which, in addition to placebo and nocebo cues, included a neutral control condition further showed that especially nocebo responses were more easily induced by this psychological placebo and nocebo manipulation. The results emphasize the great effect of psychological processes on placebo and nocebo effects. Particularly, nocebo effects should be addressed more thoroughly and carefully considered in clinical practice to prevent the accidental induction of side effects.},
  language  = {en}
}
@article{LatoschikWienrich2022,
  author    = {Latoschik, Marc Erich and Wienrich, Carolin},
  title     = {Congruence and plausibility, not presence: pivotal conditions for XR experiences and effects, a novel approach},
  series = {Frontiers in Virtual Reality},
  volume    = {3},
  journal   = {Frontiers in Virtual Reality},
  issn      = {2673-4192},
  doi       = {10.3389/frvir.2022.694433},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-284787},
  year      = {2022},
  abstract  = {Presence is often considered the most important quale describing the subjective feeling of being in a computer-generated and/or computer-mediated virtual environment. The identification and separation of orthogonal presence components, i.e., the place illusion and the plausibility illusion, has been an accepted theoretical model describing Virtual Reality (VR) experiences for some time. This perspective article challenges this presence-oriented VR theory. First, we argue that a place illusion cannot be the major construct to describe the much wider scope of virtual, augmented, and mixed reality (VR, AR, MR: or XR for short). Second, we argue that there is no plausibility illusion but merely plausibility, and we derive the place illusion caused by the congruent and plausible generation of spatial cues and similarly for all the current model's so-defined illusions. Finally, we propose congruence and plausibility to become the central essential conditions in a novel theoretical model describing XR experiences and effects.},
  language  = {en}
}